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INTRODUCTION
In combination with chemotherapy, the antitumor activity of Herceptin (anti-Her-2/neu), a humanized monoclonal antibody directed against HER-2/neu, has been effective in treatment of breast cancer cells overexpressing }IER-2/neu. This promising, FDA approved, and commercially available antibody may be effective in eradicating prevascularized miconnetastatic disease when labeled with a short lived alpha particle emitter. Alpha particles are very effective in sterilizing cells, and 1 to 3 particles transversing the cell is enough for cell kill. Therefore, this treatment approach may have the potential of eradicating micrometastatic disease both of non-overexpressing and overexpressing breast cancer cells.
In 2003, the PI moved to Johns Hopkins University, School of Medicine. The grant remained at Sloan-Kettering Institute to avoid the paperwork and expense associated with transferring the grant, instead funds were sub-contracted to Johns Hopkins and the PI has completed the work at Hopkins. This grant has led to two peer-reviewed publications, 2 abstracts and a fundable priority score (156, 8.5%ile) on an NIH RO1 grant application to continue the pre-clinical animal studies. Tasks 1-5, related to the spheroid work were completed. Tasks 6 was completed using a more realistic transgenic micromet. breast cancer model and task 7, which was not completed has been was incorporated into the NIH R01 grant application. This final report summarizes work performed on task 6 BODY
C. 1 Metastatic neu-N animal model
Using the neu-N animal model procured by R. Todd Reilly, co-investigator on this application, and also the neuexpressing NT2 tumor cell line, developed by Reilly, et al, the PI's lab has established a neu-N animal model that exhibits liver and (osteolytic) bone metastases within 3.5 to 4 weeks following LCV injection of 10 5 NT2 tumor cells. Details regarding injection methodology and anatomical delineation of the injection site are provided in Section D. Approximately 50 to 70% of attempts are successful (bright red bood at syringe tip)and 80% of successful injections lead to bone ( Fig. 1 a and b) and liver ( Fig. 2 ) metastases. Residual activity in the tail is also observed and most, likely. represents external contamination of the tail during injection. Likewise, the apparent region of high uptake (*), seen on panels 2 -4, most likely represents external contamination since no tumor was detected in this region by palpation or by subsequent necropsy of the animal. NMI imaging of this animal confirmed the skeletal metastases, histopath confirmation has been obtained.
MRI of the mouse shown in Fig. 3 was performed on a 4.7 T unit for anatomical confirmation (Fig. 4 ) of FDG observations. Images were collected approximately 3 hours after the end of FDG imaging. Over the region imaged, the MR images were consistent with widespread metastases within and emanating from the marrow spaces of the lower vertebral bodies. Tumor was also seen emanating from marrow spaces in the hind limbs. Although not highlighted in figure 3 , the multiple regions of focal uptake seen in panel 5 of Fig. 3 are consistent with the images shown on Fig. 4 and with the subsequent histopathology (not shown). Upon necropsy, multiple foci of disease were also visible about the hind limbs of this animal. No tumors could be detected by external observation of the mouse. At the time of MR imaging, however, this animal did exhibit hind limb paralysis and also a swollen abdomen, subsequently attributed to ascites accumulation resulting from onset of liver failure (Fig. 2) . Fig. 4 . A series of 0.8 mm thick, diffusion-weighted MR image slices showing multiple tumor foci, largely emanating from marrow spaces in both femurs and vertebral bodies. In slices 2 -4, the region highlighted by the broken contours depicts one such tumor, emanating from the mouse's left hind limb. The well-defined circular region of enhancement contained within the dotted contour shown on slice 3 has a horizontal (shorter) diameter of 3 mm. The rectangular regions in slices 4 and 5 depict tumor emanating from the marrow region of the right hind limb. This is most evident in slice 4 where there is a discontinuity in the zero intensity region (i.e., the bone) surrounding the marrow slit seen near the center of the rectangle. An example of this for disease emanating from marrow within a vertebral body is highlighted by the oval in slice 7. The oval in slice 6 depicts two foci of high intensity that are also most likely originating in the marrow space of vertebral bodies. Despite the large tumor burden, this mouse survived the imaging sessions (TI weighted images were also collected) antd was sacrificed soon after completion of the imaging. Histopathology demonstrated widespread disease in marrow w/ invasion. As demonstrated above, the combination of FDG and MR imaging makes it possible to survey the whole body for regions of possible tumor metastases and to then confirm selected sites by MRI. Based on the imaging studies performed to date (and presented in figures 3 and 4), the investigators propose to use FDG-[tPET and MR imaging to evaluate tumor response, in vivo, in randomly selected mice at 1 and 6 weeks after therapy (Aim 4-A-iv.).
C.2 Antibody chelation and radiolabelin'
The antibody that will be used in the proposed studies is 7.16.4. This murine antibody targets p185, the 185kD transmembraneglycoprotein product of the neu oncogene (83). The hybridoma for this antibody was originally provided to Dr. Todd Reilly, collaborator on this grant, by Dr. Mark Greene of the University of Pennsylvania, School of Medicine. Dr. Reilly and co-workers have arranged with Lofstram Labs (Gaithersburg, MD) for the on-going production of this antibody and it is available to the PI at modest cost. n. collaboration with Dr. Martin Brechbiel, 7.16.4 has been conjugated to CHXA-DTPA, the chelate that holds Bi-213, In-111 and Y-86. A 70% recovery was obtained from the chelate conjugation reaction and a CHXA-chelate-to-protein ratio of 1.23 was obtained. Chelateconjugated anti-rat IgG was used as a control antibody. A labeling efficiency averaging 60%, with specific activity ranging from 8-18 mCi/mg and radiochemical purity > 90% have been achieved. Detailed results were presented in the first submission and are not presented here to save space for new preliminary studies.
C.3 Optical imaging of NT2 tumor cell line
GFP & luceferin transfection of NT2 cells has been achieved to investigate the possibility of using this approach to monitor disease progression. Although expression was achieved (results not shown -were shown in first submission for GFP), the resulting cells exhibited reduced metastatic potential and LCV injection of transfected cells did not yield bone and liver metastases. As a result, we do not propose to use fluorescence or chemoluminscence imaging at this time. We will continue our effort to develop this approach, however.
C.4 NT2 cell radiosensitivity

1.000
The modeling, dosimetry and dose-response analyses required to A relative biological efficacy (RBE) of 3.5, consistent with published studies of other cell lines (85), is derived from these data. figure 6 . It is important to note that the spheroid studies described above were performed using an irrelevant antibody, analogous studies using 2 13Bi-labeled-7.16.4 are currently in progress. Such work will complement the in vivo studies proposed in this grant by providing an in vitro ,model that may be used to support the dosimetric modeling proposed in Aim 5.
C. 5 NT2 spheroid dose-response
C. 6 Modelina/Dosimetry Studies
Preliminary modeling/dosimetry calculations have been performed to evaluate the feasibility of using a potentially cross-reactive antibody to target metastatic disease with a short-lived alpha-particle emitter. Modeling is performed by using a multicompartmental model to solve the macrodistribution of antibody and then providing the output of this lumped parameter model as boundary conditions for a distributed parameter model that accounts for antibody diffuision and binding into a cluster of antigen positive tumor cells as well as a competing cluster of antigen-positive crossreactive tumor cells. by considering the specific energy distribution of unbound antibody to a cluster of cells compared with specifically targeted antibody. All calculations are performed for intact antibody. The analyses are founded upon work previously performed by the Pl. (33, 35, (89) (90) (91) . The preliminary results presented here demonstrate, theoretically, that the proposed approach is feasible. The studies also illustrate the modeling/dosimetry tools that will be used in analyzing the data collected in Ainms 1-4. Figure 7 illustrates the compartmental models used to simulate the macrodistribution of antibody and to provide boundary conditions for the distributed parameter cell model. GS 7/11/2005 8 body~doc The Monte Carlo (MC) code used to generate microdosimetric distributions of specific energy was validated against previously published results in which analytical solutions were obtained for tumor cells in suspension with alpha emissions on the surface of the cells or in the medium. Results comparing MC to analytical calculations are shown in figure 8. antibody into tumor clusters (note both cross reactive tissue and tumor were assumed to have the same target receptor expression). The last row of simulations shows that the added step of extravasation into nornal organ ECF (E) yields a substantially reduced cross-reactive tissue penetration (F). The quantity of interest, however, in terms of tumor efficacy and normal tissue toxicity is absorbed dose. This is obtained by first considering the radioactivity concentration. In figure 10 , kinetics of Ab penetration into tumor and cross-reactive normal tissue cell clusters are used to obtain the radioactivity concentration of 13 Bi.
• tA *.o"rn I .n side of basement membrane. The results depicted above provide substantial insight into the targeting of metastatic tumor cells and the potential toxicity of normal organs. In panel A, we see that, due to the range of 213 Bi as, the energy deposited per cell is insensitive to the exact position of the decay (surface vs cytosolic), also, since the cells are assumed close-packed the contribution from decays within the interstitial space of the cluster is negligible. Of greater interest, however, is the observation that the contribution from non-specific decays, outside the cluster, is 10-to 12-fold lower than that received if the Ab is on the surface or within the cytosol. This result is consistent with previous studies (14, 45) ; it corresponds to the situation of targeting tumor clusters in the liver or marrow when the Ab is minimally cross-reactive with these tissues. Freely circulating Ab will irradiate these rapidly accessible organ spaces substantially less than tumor cells contained within them. The inset graph of panel A depicts the absorbed dose histogram. The plot shows that almost all cells within the cluster receive an absorbed dose between 10 and 30 Gy; no cells receive zero dose. The max dose from outside the spheroid (solid triangles), in contrast, is -_ 1Gy, substantially less than the min dose to cells in the cluster. Panel B depicts the absorbed dose profile across a normal cross-reactive tissue that is only accessible after the Ab has extravasated across normal organ vasculature. The peak in energy deposition just after 20 [tm from the cluster center reflects the Bragg peak, a characteristic increase in the energy deposition near the end of an a-track associated with a rapid increase in LET as the a slows down; not seen in panel A, since energy deposition is spread out. The dose-range of irradiated cells in this case is 10 to 20-fold lower than that obtained in panel A; the majority of cells receive no absorbed dose (inset). The interaction between tumor burden, antibody administered and the size of the metastases on tumor control and normal organ toxicity is examined in figure 12 . described in the legend. This rapidly drops to zero as the tumor burden increases. As shown in panel B, however, increasing the Ab, even if the activity is kept at 60 mCi, increases TCP to 35%. Increasing both activity and Ab yields TCP > 90%. As Ab is increased beyond an optimal level, however, efficacy is reduced. The optimal Ab will depend upon tumor burden and in the case of panel B, above, corresponds to that which will saturate Ag sites on 20g of tumor cells. In all simulations depicted above, the 80 to 90% of the cells making up a 10 to 20 g cross-reactive normal tissue are expected to survive, whether this corresponds to prohibitive toxicity will depend upon the normal organ and the specific population of cells that are affected.
The theoretical studies presented in this section are preliminary and are included primarily to highlight the analytical strengths of the group and to illustrate the approaches that will be used to evaluate data obtained from the studies proposed in this application.
C.5 Ab Biodistribution, In Vivo: pSPECT/piCT imaging of 11 In-labeled 7.16.4 Ab has been performed. Imaging targeting of a 1.5-cm diam subQ tumor, inoculated 22 days prior to imaging (Fig 13) . At 1 hr no tumor localization is detected. At 6 hr Ab localization was seen at discrete points'between the tumor mass and the trunk of the animal (not shown). At 24 hr intense uptake is seen within the tumor nodule with minimal to no activity elsewhere; localization persists to 48 hr (not shown).
In contrast to the delayed Ab uptake seen for the subQ C.6 AR/Histopath-based microdosimetry: The 2 nd reviewer found that the failure to propose microdosimetry at the morphological level using AR and histopath was a significant weakness in Aim 5. As shown in the methods section of Aim 5, such an analysis is now included. Preliminary AR/Histopath-based microdosimetry has been performed. One mouse bearing a subcutaneous tumor (three weeks after inoculated with 106 NT2 cells) was injected with 65 LCi/20pg 1 1 1 1n-7.16.4. One hour after injection, the animal was sacrificed and the excised tumor was snap frozen on dry ice, embedded in O.C.T. and successive 20 lrtm sections were cut on a cryomicrotome. The slides were exposed on Kodak MS films for 24h and then stained with H&E. Histology and AR images of seven successive sections were taken at X80 and registered to each other. The size of each image is 1996x1444 pixels with calibrated 0.192 jtm/pixel. The center coordinate and size of each cell nucleus was identified with imaging analysis software (ImageJ, NIH) on each of the successive histopath images. Each AR image was divided into 20x20 pixels boxes and the mean gray values of each box were measured and saved as input with 2D coordinates of the box centers. All positions of cell nuclei were assigned with a third coordinate ranging from 10ptm to 130[tm with 20[tm separation to correspond to the slice thickness. The third coordinates of activity sources were randomly assigned assuming uniform distribution of activity in a box ±10 Qnm off the slide plane. Thus, both cell nuclei and activity positions used as input became three-dimensional. Since only tumor tissue was involved in the calculation, uniform density was assumed throughout the image and the density input matrix was not required in this situation. Standards were used to relate pixel value to activity concentration; yC of slides was also performed as a check on quantitation. Alpha-particle MC transport was carried out in this 3-D space of 384•tmx278.tmx1401Qrm containing seven successive slides. Every alpha-particle track was followed with continuous slowing down approximation and energy deposited along the track when the alpha-particle crossed a target cell nucleus was calculated as shown in the methods (Aim 5, AR-based microdosimetry). The distribution of specific absorbed dose per cell was obtained by averaging 0.7 million decays in the simulation volume. The tumor control probability (TCP) was evaluated from: TCP = exp(-N), where N is the average number of surviving cells, obtained by:
where No=4664 is the total number of cells GS 7/11/2005 identified in these slides, f,(z)dz is the number of tumor cells that are exposed to a total dose between z and z+dz Gy, and zo is the deposited specific energy that is able to reduce the cell survival probability to 37%, i.e. cell radiosensitivity. Tumor control probability at different cell sensitivity was also calculated for the cells in the simulation volume with various cumulative activities ranging from 0.1 million to 2.0 million decays. Figure 15 depicts a sample .... H&E-stained histology slide, the processed slide to identify cell nuclei, obtained from AR and yC -not shown). -Afimage, 1 h P, that was used to estimate calculation was performed involving another 6 slide sets (not shown), Plnhq-trnrk.q thrniJih n.ll ni Jc.ei spanning 130 pm. The frequency distribution of specific energy deposition in cell nuclei is shown in Fig. 16A . As shown by the distribution, all cell nuclei experience at least one alpha-particle hit (5=0). The mean specific energy, <z>, per disintegration is 7 x 10"5 Gy/Bq-s. The frequency distribution was used to derive the tumor control probability which is plotted as a function of total cumulated activity in the tumor and for different values of the radiosensitivity, zO,( Fig 16B) . As reported in the cell survival studies (Section C.4), zO = 0.9 Gy for the NT2 cell line used in these studies. 
S0.01.
0.4
The tumor control probability as a function It is important to note that the microdosimetry results presented are highly preliminary and intended primarily to demonstrate the ability to perform the kind of analysis requested by reviewer .2. The investigators anticipate a number of refinements to the initial methodology used to obtain these results. First, we anticipate using liquid emulsion AR to increase the resolution of the AR. We also expect to have an estimated cumulated activity from the 'yC studies. This will provide a single TCP value, rather than a cumulated activity dependent function. Finally, this methodology will be applied to tissue sections that include normal tissue so as to provide cell kill estimates for both tumor cell and normal cell nuclei. Although not specifically proposed in this application we will also examine the possibility of direct liquid emulsion microautoradiography of 2 13 Bi-labeled antibody.
body.doe George Sgouros, Ph.D.
KEY RESEARCH ACCOMPLISHMENTS (prior and current reporting period)
* Generated and characterized the growth of spheroids expressing different levels of HER-2/neu receptor. * Evaluated the radiosensitivities of the three cell lines used for generating the spheroids. * Characterized antibody penetration kinetics into HER-2/neu expressing spheroids.
• 
REPORTABLE OUTCOMES FOR ENTIRE PROJECT PERIOD
Peer-reviewed publications: MR images acquired on a 1.5-T whole-body MR scanner. For selected time points, 4.7-T small-animal MR images were also obtained. Images were analyzed and registered using software harmacokinetics and biodistribution of radiopharmaceudeveloped in-house. At completion of ihnaging, suspected tumor lesions were dissected for histopathologic confirmation. ticals in preclinical animal studies have generally been Blood, excised normal organs, and tumor nodules were mea-obtained by extraction of selected organs and scintillation sured by -y-counting. Tissue uptake was expressed relative to counting for radioactivity at different times after injection. the blood concentration (percentage of injected activity per This approach requires the sacrifice of multiple animals at gram of tissue [%IA/g]/%IA/g blood).
86 Y-Trastuzumab pharma-each time point, precludes the ability to monitor biodistricokinetics were used to perform 9 0Y-trastuzumab dosimetry. Results: Intraperitoneal injection of mAb led to rapid blood-pool bution in individual animals, and is partially susceptible to uptake (5-9 h) followed by tumor localization (26-32 h), as selection bias because unexpected accumulation of radioacconfirmed by registered MR images. Tumor uptake was great-tivity in tissue not collected for scintillation counting will be est for 8 6Y-trastuzumab (7 ± 1); excess unlabeled trastuzumab missed. The availability of small-animal imaging instruyielded a 70% reduction. Tumor uptake for the irrelevant mAb mentation and positron-emitting analogs of therapeutic radionuclides (e. obtain whole-body images of biodistribution, thereby reduc-cin (Gemini Bio-Products). Cell concentrations were determined ing the likelihood that areas of unexpected radiopharmaceu-by counting trypsinized cells with a hemocytometer. Tumor inoctical accumulation will be missed. Together, these increase ulum was prepared as a single-cell suspension at 1. 107 cells/mL in the statistical power of each measurement, reducing total complete RPMI 1640 medium. Each 4-to 6-wk-old female animal requirements. The disadvantages include a reduction BALB/c nude mouse (Taconic) received 0.5 mL inoculum (5.106 in quantitative accuracy and difficulty in placing the radio-cells) administered by intraperitoneal injection. Animals receiving 0.5 mL of media alone served as negative controls. activity distribution in the proper anatomic context. The
Mice were housed in filter top cages and provided with sterile latter difficulty arises because of resolution limitations and food and water. Animals were maintained according to the regubecause images of radionuclide distribution do not typically lations of the Research Animal Resource Center at MSKCC, and provide detailed anatomic information, animal protocols were approved by the Institutional Animal Care In this work, the positron-emitting radionuclide 86y, in and Use Committee. conjunction with small-animal PET (microPET) imaging, is used to evaluate pharmacokinetics and dosimetry of 90Y_ Preparation of Radioimmunoconjugate trastuzumab in a disseminated ovarian carcinoma model. mAb-chelate conjugates were provided as gifts: humanized MRI, in conjunction with image registration, was used to anti-HER-2, trastuzumab (Herceptin; Genentech, Inc.), was procorrelate the radiolabeled monoclonal antibody (mAb) dis-vided by Dr. Paul Borchardt and prepared according to Borchardt tribution with anatomy. At the end of imaging, the animals et al. chelate in all conjugation reactions. mAb conjugate was typically 86Y has a 14.7-h half-life (t, 12 ) and decays by positron supplied at 7-10 mg/mL. emission. The relatively long half-life allows the acquisition of •that the lack ofemitted photons.makes it diff'' " .icult .tit the^ CRC-15R; Capimtec) and a NaI(TI) y-counter (model 5003, Cobra (14, 15) . These references similarly outline methods for monly used is "aIn; however, with PET cameras becoming assessing reaction. efficiency using instant thin-layer chromatogramore available, the use of the positron emitter 86 Y has been phy (ITLC) and for evaluating final immunoreactivity of the prodsuggested as a better substitute. A nuclide of the same element uct. Briefly, 0.2-0.3 mL of 3 mol/L ammonium acetate was added is expected to behave chemically identically and thus serve to the (3,4) . addition of 0.040 mL of 10 mmol/L ethylenediaminetetraacetic The anti-HER2/neu mAb, trastuzumab, has demonstrated acid. Radiolabeled mAb was purified firom unbound isotope by efficacy in the treatment of cancer patients whose disease size-exclusion chromatography using a I 0-DG size-exclusion colexhibits high levels of HER2ineu expression (5,6). In sev-mumn (Bio-Rad Laboratories, Inc,). Minimum reaction efficiency exhibitsashighelevels of ITR2.Theurexpressionty5,6)thIneseveral studies, trastuzmnab has been shown to potentiate che-was 70% as determined by ITLC. The radioactivity of the eluent was determined as previously described. Specific activity varied inotherapy (7.8). The possibility of using radiolabeled anti-from 0.7 to 1.0 MBq/pig. Immunoreactivity as detennined by acid HER2/neu mAbs for cancer therapy has been previously wash was >90%. considered (9) .
MicroPET Imaging Y-trastuzumab was enhanced tumorigenicity (10). Stock T-flask cultures were propa-used as a standard. The microPET scanner used in these studies gated at 37 0 C, in 95% relative humidity, and in 5% CO 2 in RPMI was not fitted with a transmission source; therefore, transmission 1640 medium (Invitrogen) supplemented with 10% fetal calf se-studies were not collected for attenuation correction of the emisrumn (Signa), 100 units/mL penicillin, and 100 mg/mL streptomy-sion data.
MATERIALS AND METHODS
Sty-TRASTUZUMAAB liq AN OVARIAN CANCER MODEL
ground, a minimum of 15.106 true. counts per scan were collected for the liver, kidneys, spleen, and tumor. A time-activity curve for to ensure adequate image quality. This required aquisition times of blood was generated by determining the relative activity concen-2-5 min on day 0, 10-20 min on day I, and 40 min on day 2 or tration. from ROls over the heart on repeated microPET images. 3 after injection. The mice were initially anesthetized using an The curve was then scaled to fit the activity concentration in isoflurane (Forane; Baxter) loaded vaporizer (Vetequip) attached collected blood at the time of dissection by extrapolating the to an incubation chamber. The mice were thdn placed on the monoexponential clearance phase of the curve. The activity conimaging table and were kept anesthetized during the image acquicentration in liver, spleen, and kidneys was deten-nined by sition by switching the vaporizer to a fitted nose cone.
-y-counting after dissection, The shape of-tlhe blood time-activity
MRI
curve was used to construct a time-activity curve for each organ. On day 5 or 6 after injection, each mouse was imaged on a 1 .5-T Tecrewscadsottthatiity concentration of the curve whole-body MR scanner (Signa; General Electric Medical Sys-yilethmasrdcnnrtonttetmefdseto. tems) to provide anatomic images for registration with PET scans.
Tumnor kinetics were obtained using the tumor ROL. Activity Five or 6 mice were anesthetized using 106 mg/kg ketamine and concentration in dissected tumor was fit to an extrapolated plateau 5.5 mg/kg acepromasine, placed in an in-house--fabricated mouse in the time-activity curve. All curves were converted to represent coil designed for imaging up to 13 mice simultaneously ( 
Image Analysis and MicroEt Activit
Quantitationi tiastu iab , 6 1/) an X is the decay constant of 11Y Image reconstruction was performe~dby' filter~ed back'projection.
(1.0038.10-6 S-1).. In-house-developed software, IAU '(1/) and 3-dimensional inAbsorbed doses were calculated following the MIRD formalism temnal dosimetry (3D3-ID3) package (18), were used to quantitate (19), Absorbed fractions of electron energy emitted fr-om a homoreconstructed images and also for registration to MR studies, geneous distribution of " 0 Y in spheres of various sizes (20) were Whole-body clearance kinetics were obtained from the sumnmed used for tumor absorbed dose calculations. Recently published counts in each scan at each time point. Total counts were corrected mnurine-specific S factors (21) were used to calculate self and for dead time and background. The decay-corrected total counts cross-organ abobed dose for liver, spleen, and kidneys. In the for the standard obtained in this manner varied by <2% over 72 h. work cited, murine S factors were generated on the. basis of the Relative activity concentrations over the injection site, heart, and anatomic structure of an actual mouse as defined by noninvasive, tumor were obtained by drawing regions of interests (ROls). high-resolution MRI. Using the previously developed 3D-ID packMicroPET quantitation can be influenced by the position. of tissue ae(8,ogncnor eedanadterslig3dmn relative to the central axis of the camera and also by the surround-soage(1) organ ontures were novdrawnt andithireualtn 3-dimiooen insina organe volme wer convolvedia withtiit indviua radioisotopespe ing isse, ue t diferntia sesitvityandattnuatonresecpoint kernels to calculate the S--factor values. tively. Direct comparison of tunior to organ activity concentration was therefore not made; rather, only relative changes in the activity concentration in these tissues over time were evaluated. To Mini-RESULTS mize partial-volumne effects arising because the activity containing volume (e.g., tunior nodules) is below the intrinsic resolution of Tumnor Take the scanner, ROls were consistently drawn to enclose a 30-to
The efficiency of tumor formation in this ovarian carcinoma 40-[ýL volume, model was 100% (n = 23). A consistent tumor distribution.
Excised Organ Quantlitation
.pattern was observed with histologically conffirmed tu~mor nodMice were killed on day 6 after injection by CO 2 intoxication ules always appearing within 2-3 wk on the ventral side of the for dissection. Blood was collected via cardiac puncture. Organ, spleen (Fig. 1) . Tumor was also frequently found dispersed muscle, and tumor tissues were washed in phosphate-buffered within the. mescntery with small (-1I itm), dense tumor nodsaline and weighed. The samples were then counted for photons in ules formning a "beads-on-a-sti-ing" configuration. a -y-counter (mnodel 5003, Cobra II; Packard). Two 100-1.11 aliquots of the 20-miL imaging standard were used for calibration of Mi~rOPET Imaging -y-counting results. Results are expressed as the radioactivity conTime-sequential micro.PET images of coronal slices secentration in each organ divided by the concentration in blood. lected through the same plane (2 or 3 slices, -1mm, above
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This first becomes visible within 3 h and is most intense at --20 h after injection. Over this same time course tumor nodules become visible, first in the intestinal area and subsequently (e.g., by 30-40 h after injection) in the vicinity of the spleen. Tumor nodules were consistently visualized around the spleen in all animals. By 71 h, activity in the circulation is reduced and radioactivity persists at histopathologically confirmed tumor sites. In the 71-h image, the localization that is observed near the injection site corresponds to subcutaneous tumor nodules that occur as a result of the intraperitoneal tumor cell inoculation.
Corresponding coronal slices for several different control experiments are also shown on Figure 2 . In mice injected with a 100-fold excess of unlabeled trastuzumab (n = 3), tumor localization was less apparent. In tumor-free mice FIGURE 1. Dissected mouse. Arrow indicates location of (n = 3), the radioactivity distribution over time was similar small tumor nodules on spleen.
to that of the tumor-bearing mice with the exception that the dominant signal intensity arose from activity in the circuthe bed) are shown in Figure 2 . Images obtained using the lation; accumulation at sites that would typically, contain specific mAb (n = 8) show high intensity at the injection tumor nodules was not evident. The distribution pattern site and subsequent accumulation of radioactivity in the seen with the irrelevant, anti-CD33 mAb (n = 6) was circulation, as reflected by high cardiac signal intensity, similarly dominated by activity in the circulation. 
Ilaies obtained after the administration of free 86 Y (likely Pharmacokknetics
to be 86 Y-phosphate on injection; n = 4) showed, as expected, Whole-body clearance was determined from the total counts accumulation in bone, The whole skeleton was visualized in in each image set, The specific mAb had the slowest clearance these studies, with a slightly higher uptake around the various (t]/ = 160 + 10 h [mean ± SE]), but not significantly different joints. These studies were useful in ensuring that the pattern from that of the irrelevant HuMN 195 (t 1 / 2 = 150 ± 50 h) or free observed with the specific mAb was due to radiolabeled mAb 86 Y (tl2 = 140 + 50 h). Controls with an excess of unlabeled localization rather than localization of free 8 6y, as might arise specific mAb had a more rapid whole-body clearance (tl/ = because of degradation of the chelated mAb. Such a pattern 90 ± 20 h), similar to that of specific miAb in nontumorwas only observed to a small extent, at 43 h after injection for bearing mice (t 112 = 110 + 60 h). the irrelevant control studies.
The group of mice receiving the specific mAb was evaluated MRI for tumor and organ dosimetry. Initially, the activity concen- Figure 3 , illustrates the typical tumor distribution observed tration over the injection site decreased rapidly, reflecting in our model. In Fig. 3A , high-resolution transverse MR image redistribution in the circulation. This was followed by a slow slices obtained at 1.5 T are registered to corresponding micro-uptake to a plateau level due to tumor at the trocar wound site PET slices, providing anatomic context regarding the location (Fig. 4A) . Blood kinetics showed a rapid uptake phase, folof tumor nodules. The images in Fig. 3B depict multiple small lowed by a slow clearance. Tumor had an essentiallyinstan-(<I -mm diameter) tumor nodules associated with the spleen taneous uptake, slowly increasing to the stable maximum ac-(left panel) and the mesentery (right panel).
tivity concentration at around 40 h after injection (Fig. 4B ). for rad
Open symbols represent relative activity concentration (e.g., q ius = 0.1 mm to 3.7 GyiMBq for radius pharmacokinetics) derived from repeated microPET imaging. 5 mm. Results are summarized in Table 1 . Activity concentrations (%lA/g) in dissected tissue (solid symbols) were used to quantitate image-based relative concentra-DISCUSSION tions. Error bars represent combined standard uncertainty.
Lines show fits used for cumulated activity calculations.
There is now a preponderance of evidence to suggest that radioimmunotherapy will be most successfiil in the treatment
Biodistribution
The radioactivity distribution, obtained by well scintilla-TABLE I tion (-y) counting of excised tissues is shown in Spleen had the second highest uptake for the specific Tumor o Tfii-• siaf sea-e e (22) (23) (24) . Most animal models eval-CONCLUSR-ON... uating tumor response rely on tumor volume measurements For all injected compounds, the relative microPET image obtained by external, caliper-based measurements. Because intensity of the tumor matched the subsequently determined this approach is not amenable to the evaluation of therapy 8 6y uptake. Coregistration with MR images confirmed the against micrometastases, the preclinical evaluation of such is position of 86 y uptake relative to various organs. Radiolausually performed by assessing animal morbidity, secondary to beled trastuzumab mAb was shown to localize to sites of macroscopic growth of the micrometastases (12) . Using a disease with minimal normal organ uptake. Dosimetry calpositron-emitter-labeled mAb and microPET imaging we have culations showed a strong dependence on tumor size. These demonstrated the ability to image, monitor targeting kinetics, results demonstrate the usefulness of combined microPET and perform dosimetry of micrometastases at clinically rele-and MR] for the evaluation of novel therapeutics. vant dimensions, noninvasively.
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lowship. Relative to other small-animal imaging modalities (e.g., optical and MRI), microPET is characterized by a very high REFERENCES sensitivity but limited resolution. The high sensitivity is of I. Gordon INTRODuCTi on The objective of this study was to investigate the efficacy of te auanized poroclal an tibd titrastuzurnab labeled with the ce-particle emitting atomic rected against HER2/neu, particularly in combination with generator, actinium-225 (22 5 Ac), against breast cancer sphechemotherapy, has been effective in the treatment of breast roids with different HER2/neu expression levels.
22 'Ac has a cancer malignancies overexpressing HER2/neu (1-4). This 10-day half-life and a decay scheme yielding four otwork examines a treatment approach using trastuztmab labeled particles, with the at-particle emitting atomic generator, actinium-225 Experimental Design: The breast carcinoma cell lines (" 2 'Ac), to eradicate breast cancer metastases expressing vari-MCF7, MDA-MB-361 (MDA), and BT-474 (BT) with relaable levels of HER2/neu. tive HER2/neu expression (by flow cytometry) of 1:4: 18 The HER2/neu oncogene encodes a transmembrane protein were used. Spheroids of these cell lines were incubated with (p1 85 imm) with extensive homology to the epidermal growth different concentrations of 2 25 Ac-trastuzumab, and spheroid factor receptor. Amplification and overexpression of HER2/neu growth was measured by light microscopy over a 50-day have been documented in many human tumors, most notably in period, breast cancer (5, 6). The expression of HER2/neu is relatively Results: The activity concentration required to yield a stable over time and is generally congnuent at different meta-50% reduction in spheroid volume at day 35 was 18.1, 1.9, static sites (5, 7). However, lER2neu protein has also been identified on cell mnembranes of epithelial cells in the gastroin-BT spheroids, respectively. MCF7 spheroids continued testinal, respiratory, reproductive, and urinary tract, as well as in growing but with a 20-30 day growth delay at 18.5 kBq/mlc the skin, breast, and placenta. HER2/neu expression levels in growiAg sp i gwith was03 deaygrowthdedlby 3a-408daya these non-ral tissues are similar to the levels found in nonamkBq/ml; at 18.5 kBq/ml, 12 of 12 spheroids disaggregated plified, nonoverexpressing breast cancers cells (6). Approxiafter 70, days and cells remaining from each spheroid failed mately 30% of breast cancer patients have tumors overexpressto form colonies within 2 weeks of being transferred to ing the HER2/neu receptor. Trastuzumab treatment has been adherent dishes. Eight of 10 BT spheroids failed to regrow at limited to these patients because of the cross-reactivity with 1.85 kBqm. All of the BT spheroids at activity -normal tissues noted above. HER2/neu has been considered previously as a target for radioimnmnotherapy against breast cancer. The radionuclides, 1311, 1251, 186Re (8, 9) , the positronemitter, 8 6 y (10), and also 212 Pb (I1), of which the daughter, 2 12 Bi, decays by ct-particle emission, have been labeled to Received 12/24/03; revised 2/25/04; accepted 3/1/04.
antibodies targeting HER2/neu and investigated in animal 'Ac leads to the emission The costs of publication of this article were defrayed in part by the of four a particles (Fig, 1) , greatly increasing its efficacy over payment of page charges. This article must therefore be hereby marked previously considered a-particle emitters (12) (13) (14) . Studies, in advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
vitro and in animal models, have shown that this radionuclide is Requests for reprints: 720 RutlandAvenue, Ross 220, Department of -1000-fold more effective per unit radioactivity than 2 13 Bi, a Radiology, Johns Hopkins Medicine, Baltimore, MD 21205. first generation at-emitter that is currently under clinical inves- supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 jig/ml streptomycin. The cell cultures were kept 6.4"MeV at 37'C in a humidified 5% CO 2 and 95% air incubator. Spheroids. Spheroids were initiated using the liquid that depending on the administration route, target, and chelation 200. chemistry, it is also substantially more toxic (17) (18) (19) . The in- Ac has a longer half-life (10 days versus 45,6 min for 2t3 Bi), increasing the total number of IS0 decays per unit of radioactivity, allowing prolonged in'adiation 0 of targeted cells, and because its decay leads to the release of. three ce-particle emitting daughters. The toxicity arises because mC 100 E chelate conjugated antibody delivery of this radionuclide can only retain, within the chelate, the first of the four ce-emitting Distance from surface (gm) ing 0.25% trypsin and 1 mm EDTA. Light microscopy was used washes and incubations were performed in FAGS buffer (PBS to monitor the mixture for spheroid dissociation and membrane +0.5% BSA +0.02% NaN6). Cells were washed twice and blebbing as an early indicator of meobrane rupture. Dissociaresuspended at 1-2 X 10' cells/mi. A lOO-pli aliquot was tion normally occurred within 2 mn, during which blebbing of incubated with trastuzumab for 0.5 h on ice. Cells were again cells was minimal. The suspension was immediately centrifuged washed twice and resuspended in 100 onl buffer. The secondary, at 75 X g for 45 s to remove trypsin and the pellet resuspended fluorescently tugged antibody, against the F. portion of human in PBS for flow cytometry. sgG (Sigma; F-9512), was added and the suspension incubated Flow Cytonvetry. The relative level of HER2/deu exon ice for 0.5 h. After a final two washes, cells were resuspression for the three cell lines was determined using the pended in 2 in of cold buffer and analyzed. A total of 10,000 Becton-Dickinson FACSCalibur Analyzer (Franklin Lakes, NJ).
events were collected for each cell line. HER2/neu expression was determined for cells from both monoAntibodies. Trastuzurmab (anti-suaMeie; Genentech, layer culture and from disaggregated spheroids, All of the Inc., South San Francisco, CA) was used as the specific anti- 
ci
Radiolabeling. Details regarding the radiolabeling meth-I• .E-03 odology are described in reference (13) . "for 30-45 min.
.0E.02 0
The second step in construct preparation was the The reaction mixture was then heated to 36'C for 30-60 min. acid to complex any free metals during the size exclusion kBq/ml actinium-225-labeled nonspecific antibody, corresponding to chromatographic purification using a 10 DG size exclusion absorbed doses of 0.7. 3.4. and 6.8 Gy, respectively; bars, ±SE.
column with a 1% hutman serum albumin as the mobile phase.
The radiochemical purity of Confocal Microscopy. Spheroids of diameter 200 jLnm External beam radiosensitivity was determined after exposure to were incubated with 10 jLg/ml FITC-(F7250; Sigma, St. Louis, acute doses of 3, 6, 9, or 12 Gy photon irradiation using a MO) conjugated trastuzumab for 1, 3, and 5 h and imaged by cesium irradiator at a dose rate of 0.8 Gy/min (Cs-137 Model confocal microscope (Zeiss LSM 510; Carl Zeiss, Inc.
68; JL Shepherd and Associates, Glendale, CA.). The absorbed Oberkochen, Germany) while still in incubation mediumn. A dose required to yield a 37% survival in the log-linear portion of 3-ftm-thick optical section was acquired at the center of each the surviving fraction curve (i.e., the DO value) was obtained by spheroid. Five spheroids were imaged for each time point, fitting a monoexponential function to this portion of the curve. Antibody concentration as a function of radial distance was obtained using MIAU, a software package developed in-house (23) . The method has been described previously (24) . Briefly, an erosion element is used to follow the exterior contour of each Table I Dose, Do, required to reduce surviving fraction of celils in spheroid, and the average pixel intensity in each ring is conmonolayer cultures following external beam and n-particle irradiation verted to antibody concentration by calibration with the known to 0:37 external concentration of antibody. The antibody concentration
External beam a-Particle as a function of distance from the rim of the spheroid was Cell line Do (Gy) Do (Gy) corrected for light attenuation as described previously (24 
Time (d)
Monolayer cultures incubated with 3.7, 18.5, and 37 kBq/ml treated spheroids (control) were followed in the same manner.
225
Ac-labeled nonspecific antibody for 24 h were used to deTwenty-four or 12 spheroids were used in each experiment. termine ot-particle radiosensitivity. Over a 24-h period, 6.7% of After incubation, the spheroids were washed three times by the total number of 225 Ac atoms will have decayed. Because the suspension in fresh medium and placed in separate wells of a longest-lived daughter, Bi-213, has a half-life of 45.6 min, all of 24-well plate. The medium in each well was replaced, and the daughters generated during this period will also decay.
individual spheroid volume measurements were performed Assuming, therefore, that each decay of 225 Ac deposits one-half twice per week. An inverted phase microscope fitted with an (to account for cells settling to the bottom of the plate and, ocular micrometer was used to determine the major and minor therefore, being irradiated only from one side) of the sum of all diameter d,,,_.
• and d,,,,,,, respectively, of each spheroid. Spheroid four of the a-particle energies, the mean absorbed dose is volume was calculated as V = Tr~d__.d,,,.2 / 6. Volume monestimated to be 0.7, 3.4, and 6.8 Gy for each of the three itoring was stopped once a spheroid diameter exceeded 1 mm or concentrations, respectively. when the spheroid fragmented to individual cells or smaller The radiosensitivity of spheroids was evaluated as the (2-3-cell) clusters. The viability of such fragments was assessed activity concentration required to reduce the treated to untreated in an outgrowth assay by plating the cell clusters on to adherent spheroid volume ratio to 0,37. Because this parameter depends dishes, incubating for 2 weeks, and then evaluating for colony on the day post-therapy, volume ratios from day 20 to day 45 fonnation or outgrowth. after therapy were calculated for each spheroid, and the median value across this time period was used. By plotting this voltmne ratio versus activity concentration and fitting the log-linear RESULTS portion of the curve to a monoexponential function, a radiosenThe relative HER2Ineu cell-surface expression of MCF7, sitivity parameter may be derived firom the slope. The inverse of MDA, and BT cells derived from monolayer culture and from the slope gives the dose that yields a volume ratio of 0.37. This disaggregated spheroids is depicted in Fig. 2 . The highest value is denoted "DVR 37 ," and it is loosely analogous to the Do HER2/neu expressing cell line, BT, shows a decrease in the in colony formation assays.
number of HER2/neu sites (relative to MDA) and also a greater Treatment Protocol. The response to Ac-Trastuzumab measuring FITC-labeledtrastuzumab by confocal microscopy.
10o00
Images acquired through the equator of 200-prm diameter spheroids incubated for 1, 3, and 5 h with 10 pLg/ml trastuzurnab-FITC are shown for MDA and BT spheroids in Fig. 3A . The . 10 cells on the spheroid rim are clearly outlined, consistent with .0 antibody localization to cell-surface HER2/neu, Trastuzumab. has penetrated -1, 2, and 3 cell layers after 1-, 3-, and 5-h incubation, respectively. FITC intensity was converted to anti-1.1 body concentration as described in "Materials and Methods." The results are depicted in Fig. 3, B and C. After l-h incubation, ioo.o the concentration of antibody on the surface of BT spheroids is . greater than twice that on the surface of MDA spheroids. At a depth of 20 pRm, the antibody concentration in BT spheroids is .ao 5-fold greater than in MDA spheroids.
To examine for a possible differential sensitivity to unla-0 beled trastuzumab antibody, spheroids of the three cell lines C 1
were incubatedfor I h in 10, 50,100, and 500 p4g/ml No impact on spheroid growth was observed (data not shown).
To discriminate between inherent radiosensitivity of the 10000-different cell lines and increased targeting due to the differential expression of HER2/neu, the radiosensitivity of each cell line 10o0
was determined in monolayer cultures as well as by following spheroid growth after external beam irradiation and after incubation with 22 5
-Ac-labeled nonspecific antibody. The surviving fraction of cells in monolayer culture is plotted versus mean absorbed dose for photons and a-particles in Fig.. 4, A and 
Time (d)
cells, respectively. Although this cell line is also more sensitive Fig. 6 Median growth curves for spheroids incubated I h with 0.37 (*), to a-particle radiation than MDA and BT, the differences in 1 Ac-labeled nonspecific radiolabeled antibody, outgrowth (radioactive control) are depicted in Fig. 6 . A.t day 35, the assays for MCF7 and MDA spheroids yielded no colonies; for median volume of spheroids treated with 18.5 kBq/ml 225 Ac-BT the same result was obtained only at the highest radioactivity trastummnab relative to spheroids incubated for 1 h with 22 5 Acconcentration used. The dose required to reduce the volume labeled nonspecific antibody (radioactive control) was 52%, ratio of treated to untreated spheroids to 0.37, denoted DVR 37 , 1.4%, and 0.3% for MCF7, MDA and BT, respectively. The was used as a measure of spheroid radiosensitivity and is listed 2 25 Ac activity concentration required to yield a 50% reduction in Table 2 . The DVR 37 results show no difference among in spheroid volume relative to the radioactive controls at day 35 spheroids of the three cell lines in sensitivity to external beam was 18.1, 1.9, and 0.6 kBq/ml (490, 52, 14 nCi/ml) for MCF7, irradiation. Differences in volume response to u-particle irradi-MDA, and BT spheroids, respectively. Growth of individual ation are seen, however, with MCF7 almost a factor of 2 more spheroids after 1 h of incubation with increasing concentrations sensitive than MDA. of 225 Ac on 10 ig/mIl trastuzumab are shown in Fig. 7 . The variability in response of individual spheroids was minimal. At an activity concentration of 1.85 kBq/ml, 2 of 12 BT spheroids Table 2 Dose required to reduce the treated to untreated spheroid were viable; no colonies were observed at 3.7 and 18.5 kBq/ml volume ratio to 0.37 (DVR 37 ) for this cell line. Likewise, no colonies were observed for MDA External beam DVR 3 7 ot-Particle DVR 37 spheroids treated at 18.5 kBq/ml. Fig. 8 Ac-trastuzumab is allowed to distribonly if two fundamental problems are addressed. First, the high ute for several hours and is then cleared from the circulation, background expression of HER2/neu in normal tissues must be either by direct physical means such as plasmapheresis or imobviated, as this cross-reactivity is likely to lead to ct-particle munoadsorption (27, 28). Extravasation of intact antibody into irradiation of normal tissues. Second, the potential toxicity normal tissue parenchyma generally reqcuires 24-48 h (29) . By associated with the distribution of free, oL-particle emitting rapidly decreasing the concentration of circulating antibody, daughters resulting from the decay of 225 Ac must be overcome, binding to normal cross-reactive tissues would be reduced sub- Ac-Trastuzurnab stantially, whereas also reducing the 125Ac concentration in the that the radiosensitivity parameter defined in this work for circulation and, therefore, the subsequent concentrations of free spheroids is not a measure of cell sterilization but rather of daughters.
volume reduction. Volume reduction encompasses a number of We have used the spheroid model as a preliminary in vitro biological variables including the rates of cellular sterilization, model to examine the feasibility of targeting breast cancer removal of sterilized cells, and cellular proliferation. micrometastases using trastuzumab labeled with the atomic As in other studies investigating the relationship between at-particle generator, 225 Ac. In particular, the efficacy against HER2/neu expression and growth inhibition using chemotheratumor cell clusters with different expression levels of HER2/neu peutic and biological agents (30, 34) , the response of spheroids was examined. As demonstrated by flow cytornetry, the three to ficity relative to the radioactive controls was observed. This is (30) . Differences in the actual values may be explained by the because targeted spheroids are exposed to the atomic a-particle different agents and incubation conditions used to perform the generator for a prolonged time period due to binding and retenmeasurements, In a previous report (30) , cells were incubated tion of the antibody. Longer radioactive control exposure durawith the murine-derived anti-HER2/neu antibody 4D5 and also tions such as the 24-h period used in the radiosensitivity measwith a fluorescently labeled F(ab') 2 fragment of goat antimouse urements showed volume reductions similar to those obtained IgG. In the current studies, incubation was carried with the with the 1 h specific antibody incubation. The very high spechumanized version of 4D5, trastuzumab. The cells were subseificity seen with a short exposure tine supports the clearing quently incubated with a commercially available fluorescently strategy outlined above. tagged antihmnan F. antibody.
In conclusion, we have demonstrated the ability to increase Antibody penetration relative to cell-surface antigen denthe efficacy of trastuzutmab against clusters of tumors cells sity was also examined. The trastuzunab concentration in BT expressing intermediate levels of HER2/neu by labeling trastuspheroids after 1-h incubation was found to be a factor 2-3 zumab with the a-particle emitting atomic generator, 225 Ac. higher than for the MDA spheroids, whereas the peiletration These results suggest that an 225 Ac concentration in the range depth into the spheroids was similar. The antibody concentration 0.6-2 kBq/ml (20-75 nCi/ml) may be sufficient to achieve a used is close to the average receptor concentration within the substantial reduction in the number of tumor cells with interspheroid. Assuming 106 receptors per cell (31) and -4 × 10"' mediate HER2/neu expression. This translates to approximately cells/liter (24) , the concentration of receptor sites within the BT 0.07-0.3 mCi for human administration. On the basis of animal spheroid is -660 nm. Because 10 .tg/ml intact antibody transstudies, we expect that this activity concentration will be clinlates to -670 nm, the concentration of antibody matches, and, ically implementable. due to the large antibody supply, would saturate available cellsurface receptor sites (27, 32). The confocal microscopy studies are consistent with this analysis.
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